|
gptkbp:instance_of
|
gptkb:pharmaceuticals
gptkb:brand
|
|
gptkbp:approves
|
gptkb:2004
gptkb:FDA
|
|
gptkbp:associated_with
|
gptkb:John_Cunningham_virus
|
|
gptkbp:atccode
|
L04 AA23
|
|
gptkbp:available_on
|
gptkb:brand
|
|
gptkbp:brand
|
gptkb:pharmaceuticals
|
|
gptkbp:casnumber
|
154063-25-1
|
|
gptkbp:chemical_formula
|
C6460 H10000 N1716 O2000 S42
|
|
gptkbp:class
|
gptkb:monoclonal_antibody
|
|
gptkbp:clinical_trial
|
numerous
Phase III
AFFIRM study
CROHN study
ENCORE study
|
|
gptkbp:clinical_use
|
neurology
gastroenterology
long-term treatment
|
|
gptkbp:community_health
|
important
|
|
gptkbp:competitors
|
gptkb:Tecfidera
gptkb:Ocrevus
gptkb:Aubagio
|
|
gptkbp:contraindication
|
active infections
history of PML
hypersensitivity to natalizumab
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
gptkbp:drug_interactions
|
possible
immunosuppressants
live vaccines
|
|
gptkbp:duration
|
monthly
long-term
|
|
gptkbp:effective_date
|
gptkb:2004
|
|
gptkbp:financial_support
|
available
Tysabri Access Program
|
|
gptkbp:formulation
|
sterile solution
|
|
gptkbp:healthcare
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tysabri
|
|
gptkbp:indication
|
gptkb:relapsing_forms_of_multiple_sclerosis
moderate to severe Crohn's disease
|
|
gptkbp:ingredients
|
gptkb:natalizumab
|
|
gptkbp:injection_site_reactions
|
possible
|
|
gptkbp:invention
|
patented
|
|
gptkbp:investment
|
gptkb:progressive_multifocal_leukoencephalopathy
|
|
gptkbp:is_monitored_by
|
yes
|
|
gptkbp:manufacturer
|
gptkb:Biogen
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
Tysabri brand
|
|
gptkbp:mechanism_of_action
|
integrin inhibitor
|
|
gptkbp:monitoring_requirement
|
JCV antibody testing
|
|
gptkbp:monitors
|
0 B8 B1 D1 B1 A
|
|
gptkbp:patient_education
|
required
|
|
gptkbp:patient_population
|
gptkb:children
adults
|
|
gptkbp:pharmacokinetics
|
monoclonal antibody pharmacokinetics
|
|
gptkbp:previous_name
|
gptkb:natalizumab
|
|
gptkbp:price
|
high
high-cost medication
|
|
gptkbp:provides_guidance_on
|
available
MS treatment guidelines
Crohn's disease treatment guidelines
|
|
gptkbp:reimbursement
|
insurance coverage
|
|
gptkbp:requires
|
available
|
|
gptkbp:research
|
ongoing
|
|
gptkbp:research_focus
|
gptkb:neurodegenerative_diseases
autoimmune diseases
|
|
gptkbp:risk_of_progressive_multifocal_leukoencephalopathy
|
increased
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:safety_measures
|
yes
MRI scans
|
|
gptkbp:service_frequency
|
every 4 weeks
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
allergic reactions
infections
documented
infusion reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:symbolism
|
yes
|
|
gptkbp:trade
|
gptkb:natalizumab
gptkb:Tysabri
|
|
gptkbp:treatment
|
variable
disease modification
|
|
gptkbp:type_of_care
|
important
important for efficacy
|
|
gptkbp:type_of_insurance
|
varies
|
|
gptkbp:used_for
|
gptkb:Crohn's_disease
gptkb:multiple_sclerosis
|
|
gptkbp:website
|
intravenous infusion site
|
|
gptkbp:bfsParent
|
gptkb:EMD_Serono
gptkb:Biogen_Idec
gptkb:Biogen_Inc.
gptkb:BIIB
|
|
gptkbp:bfsLayer
|
5
|